Heller myotomy for oesophageal achalasia: risk factors for reintervention - a narrative review [0.03%]
赫勒肌切开术治疗贲门失迟缓症再手术的风险因素-叙事性综述
Arianna Vittori,Renato Salvador,Luca Provenzano et al.
Arianna Vittori et al.
Introduction: Heller myotomy (HM) is an effective and durable treatment for esophageal achalasia. However, some patients experience persistent or recurrent symptoms that require reintervention. Heterogeneous definitions o...
Optimizing nutritional care across the continuum from intensive care to recovery: an expert opinion review [0.03%]
从重症监护到恢复期的营养护理连续性优化：专家意见回顾
Arthur R H van Zanten,Pavel Kohout,Elisabeth De Waele et al.
Arthur R H van Zanten et al.
Introduction: Survivorship after critical illness is frequently complicated by muscle wasting and gastrointestinal (GI) dysfunction, driving prolonged functional impairment. Nutrition is a modifiable determinant across th...
Recent developments in the therapeutic management of acid-related gastrointestinal diseases [0.03%]
酸相关性胃肠疾病治疗的最新进展
Aitor Lanas-Gimeno,Angel Lanas
Aitor Lanas-Gimeno
Introduction: Acid-related gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), remain major global health burdens despite decades of proton pump inhibitor (PPI)-b...
Immunotherapy plus chemotherapy in advanced biliary tract cancers: pros and cons [0.03%]
免疫疗法联合化疗在晚期胆道癌中的利弊分析
Gagandeep Brar,Juan W Valle
Gagandeep Brar
Introduction: Biliary tract cancers (BTC) are highly immunosuppressive 'cold' tumors with limited treatment options. In unresectable or advanced-stage disease, the combination of immune checkpoint inhibition with chemothe...
Kizuki Yuza,Miho Akabane,Jun Kawashima et al.
Kizuki Yuza et al.
Introduction: Although immune checkpoint inhibitor (ICI)-based combinations have established the frontline standard for advanced hepatocellular carcinoma (HCC), substantial unmet needs persist-limited response rates, prim...
Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively? [0.03%]
克罗恩病的抗纤维化治疗：炒作还是现实？肠道纤维化能被有效靶向吗？
Sailish Honap,Axel Dignass,Vipul Jairath et al.
Sailish Honap et al.
Introduction: Fibrostenotic Crohn's disease remains a major unmet clinical need, as currently licensed therapies primarily target inflammation and have not been shown to prevent fibrosis progression or reverse established...
Management of gastric varices: treatment options and opportunities to improve outcomes [0.03%]
胃静脉曲张的治疗选择及改善预后的机遇
Michael B MacIsaac,Alex Wynne,Peter Hayes
Michael B MacIsaac
Introduction: Gastric varices represent a challenging clinical scenario due to the severity of consequences when bleeding occurs, the cohort of patients in which it occurs and a paucity of high-quality prospective data to...
FAPI PET in inflammatory bowel disease: a novel window on fibroblast activity, with unanswered clinical questions [0.03%]
炎症性肠病中的FAPI-PET：观察成纤维细胞活性的新窗口及尚待解答的临床问题
Luca Filippi,Esra Arslan,Halil Komek et al.
Luca Filippi et al.
Accurate assessment of inflammatory activity in inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) remains a major clinical challenge. Positron emission tomography (PET) with fibroblast activation pro...
Fahmi Shibli,Raúl Alberto Jiménez-Castillo,Ronnie Fass
Fahmi Shibli
Introduction: The Lyon 2.0 consensus was established to further refine the original Lyon consensus and address gaps in reflux testing and endoscopic diagnosis of GERD. It represents a significant advancement in the diagno...